PATIENT SUPPORT PROGRAMS (PSP) MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Patient Support Programs (PSP) Market Size and Forecast – 2025 to 2032

The Global Patient Support Programs (PSP) Market is estimated to be valued at USD 22.70 Bn in 2025 and is expected to reach USD 68.95 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.2% from 2025 to 2032. This significant growth can be attributed to the increasing prevalence of chronic diseases, rising healthcare costs, and growing need for patient-centric care.

Key Takeaways of the Global Patient Support Programs (PSP) Market:

• By Service Type, Medication Adherence Support is expected to hold the largest market share of 22.6% in 2025.
• By Therapeutic Area, the Oncology segment is expected to lead the global patient support programs (PSP) market with a 32.1% share in 2025.
• By Age Group, the Pediatric segment is projected to account for the largest share of 43.4% in 2025.
• North America is expected to lead the market, holding a share of 38.3% while Asia Pacific is anticipated to be the fastest-growing region, with a market share of 32.4% in 2025.

Market Overview:

Market trends include a shift towards the adoption of digital health solutions and personalized support programs. Pharmaceutical companies are investing in the development of innovative patient support programs that leverage advanced technologies such as artificial intelligence, machine learning, and data analytics to improve patient outcomes and enhance adherence to treatment plans. Additionally, there is a growing emphasis on collaborations between healthcare providers, payers, and pharmaceutical companies to create integrated and comprehensive patient support programs that address the unique needs of each patient.

Currents Events and Their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Patient Support Programs (PSP) Market Insights, By Service Type - Medication Adherence Support dominates due to the critical need for ensuring patient compliance in chronic care management

In terms of Service Type, Medication Adherence Support is expected to account for the highest market share of 22.6% in 2025, owing to the growing importance of ensuring patients take their prescribed medications as directed. Non-adherence to medication regimens is a significant problem in healthcare, leading to poor patient outcomes, increased healthcare costs, and a higher risk of complications. Patient Support Programs (PSPs) that focus on medication adherence support aim to tackle this issue by providing patients with the tools, resources, and support they need to stay on track with their treatment plans.

One of the key factors driving the adoption of medication adherence support services is the increasing prevalence of chronic diseases, such as diabetes, cardiovascular disorders, and respiratory conditions. For instance, In December 2024, according to the WHO data, noncommunicable diseases (NCDs) accounted for 43 million deaths in 2021, representing 75% of non-pandemic-related deaths worldwide. Premature deaths from NCDs affected 18 million people under 70, with 82% of these in low- and middle-income countries (LMICs). These conditions often require long-term medication management, and patients may struggle to maintain adherence over time. PSPs that offer medication adherence support can help patients develop better habits, understand the importance of taking their medications as prescribed, and overcome any barriers to adherence, such as forgetfulness or side effects.

Patient Support Programs (PSP) Market Insights, By Therapeutic Area - Oncology leads due to the complex nature of cancer care requiring comprehensive support services

In terms of Therapeutic Area, the Global Patient Support Programs (PSP) Market is projected to be dominated by the Oncology segment with share of 32.1% in 2025. This can be attributed to the complex nature of cancer care, which often involves multiple treatments, side effects, and emotional challenges for patients and their families. PSPs in the Oncology space aim to provide comprehensive support to cancer patients throughout their treatment journey, addressing their physical, emotional, and practical needs.

One of the primary factors driving the growth of the oncology segment is the increasing incidence of cancer worldwide For instance, in February 2024, the World Health Organization (WHO) and its cancer research arm, the International Agency for Research on Cancer (IARC), reported that 20 million new cancer cases and 9.7 million deaths occurred globally in 2022. About 1 in 5 people develop cancer in their lifetime, while 1 in 9 men and 1 in 12 women die from it.  As more people are diagnosed with cancer, there is a growing demand for support services that can help patients navigate the challenges of treatment and recovery. care coordination, which can significantly improve the quality of life for cancer patients and their families.

Patient Support Programs (PSP) Market Insights, Pediatric segment dominates as they address the unique needs of young patients and their families in navigating complex treatment journeys

In terms of By Age Group, the Pediatric segment contributes the highest share of the Global Patient Support Programs (PSP) Market with share of 43.4% in 2025. This can be attributed to the unique challenges faced by pediatric patients and their families, as well as the growing recognition of the importance of providing comprehensive support to this vulnerable population.

Children with chronic or serious illnesses often require specialized care and support that goes beyond the scope of traditional healthcare services. PSPs in the pediatric segment aim to address these needs by providing a range of services tailored to the specific requirements of young patients and their families. These services may include disease education, emotional support, care coordination, and financial assistance, among others.

Role of AI in the Patient Support Programs (PSP) Market:

• Artificial Intelligence (AI) is fundamentally transforming the patient support programs (PSP) market by streamlining processes, enabling cost efficiencies, and driving data-driven decision-making across the patient journey. AI-powered predictive analytics helps PSP providers identify patients at risk of non-adherence or disease progression, enabling proactive interventions. AI also facilitates personalization at scale, tailoring communications, medication reminders, and educational content based on patient behaviour, preferences, and medical history. Process automation is another key benefit—AI-driven tools handle repetitive tasks such as appointment scheduling, medication tracking, and data entry, reducing administrative burden and freeing up resources for more meaningful patient interactions. Additionally, AI-powered chatbots and virtual assistants provide round-the-clock patient support, offering timely responses and guidance, which improves overall patient engagement and satisfaction.
• A notable example is CareCentrix, a U.S.-based healthcare services company specializing in post-acute care management, which leverages AI within its patient support ecosystem. CareCentrix’s AI-enabled CarePredict platform analyzes patient data to predict potential hospital readmissions and enables timely interventions through its PSP framework. This not only improves patient outcomes but also optimizes healthcare resource utilization. While AI opens doors to new business models such as digital therapeutics and remote care services, it also presents challenges, including data privacy concerns, algorithm transparency, and the need for ongoing human oversight. For long-term success, companies in the patient support programs (PSP) market must integrate AI in a way that complements human empathy, prioritizes ethical AI practices, and maintains a strong focus on patient-centricity, ensuring technology enhances rather than replaces personalized care.

Regional Insights

To learn more about this report, Request sample copy

North America Patient Support Programs (PSP) Market Analysis and Trends

North America is projected to dominate the global patient support programs (PSP) market with share of 38.3% in 2025. The region boasts a well-established healthcare infrastructure, coupled with a high adoption rate of innovative patient support solutions. The presence of major pharmaceutical companies and their significant investments in PSPs further contribute to the market's growth. Moreover, favorable government policies and initiatives aimed at improving patient outcomes and reducing healthcare costs have created a conducive environment for the market's expansion.

Notable companies in the region, such as McKesson Corporation and UnitedHealth Group, have played a pivotal role in driving the adoption of PSPs through their comprehensive offerings and extensive network. For instance, in February 2024, Redi Health, a U.S.-based digital health solutions provider founded to bridge gaps in patient care, raised USD 14 million in Series B funding, led by Blue Heron Capital. The platform connects patients, providers, and pharma companies, offering features like daily medication reminders, symptom tracking, financial assistance, and brand-specific content.

Asia Pacific Patient Support Programs (PSP) Market Analysis and Trends

The Asia Pacific region is projected to exhibit the fastest growth in the global patient support programs (PSP) market with share of 32.4% in 2025. The rapid growth can be attributed to the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing awareness about patient-centric care. For instance, On March 2025, IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) calls for global action on NCDs (Non-Communicable Diseases), which account for 75% of global deaths. Investing an extra 1% of GDP (Gross Domestic Product) in healthcare, with 40% allocated to NCDs, could save 5 million lives annually, says Airfinity research. The region's vast population, coupled with the improving healthcare infrastructure, presents significant growth opportunities for market players.

Governments in countries like China and India are actively promoting the adoption of PSPs to enhance patient care and streamline healthcare delivery. Additionally, the increasing penetration of digital technologies and the rise of local pharmaceutical companies are contributing to the market's growth. Companies such as Tata Consultancy Services and Wipro Technologies are leveraging their expertise in technology and healthcare to develop innovative PSP solutions tailored to the region's needs.

Global Patient Support Programs (PSP) Market Outlook for Key Countries

U.S. Patient Support Programs (PSP) Market Trends

The U.S. market for patient support programs is characterized by a strong emphasis on patient-centric care and the adoption of innovative technologies. The country's healthcare system, driven by private insurance and government programs like Medicare and Medicaid, has been a key driver for the adoption of PSPs. Major pharmaceutical companies and healthcare providers in the U.S. have been at the forefront of developing and implementing comprehensive PSPs to improve patient outcomes, enhance medication adherence, and reduce healthcare costs.

For instance, in September 2024, SEQSTER, a U.S.-based health tech company that unifies patient data from multiple sources, partnered with PatientsLikeMe, a health network where users track conditions, treatments, and labs. Through the collaboration, SEQSTER becomes the electronic health record (EHR) provider for PatientsLikeMe, enabling its 1 million members to access and use their medical data for better decision-making and participation in research or clinical trials.

India's Patient Support Programs (PSP) Market Trends

India's patient support programs (PSP) market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, high out-of-pocket healthcare expenditures, and the expansion of digital health infrastructure. Technological advancements are also playing a crucial role; However, opportunities abound in expanding PSP coverage in underserved regions, leveraging artificial intelligence for personalized care, and fostering collaborations between stakeholders to demonstrate measurable clinical outcomes.

For instance, in November 2022, Roche Pharma India, a global healthcare company, launched the Blue Tree 2.0 mobile app to streamline access to its Blue Tree Patient Support Programme in India. Available for Android and iOS, the app simplifies enrolment, tracks free drug requests, provides doorstep delivery with live order tracking, and offers reminders for infusion schedules, free consultations, diagnostic tests, and financial assistance like interest-free EMIs.

China Patient Support Programs (PSP) Market Trends

China's market for patient support programs is experiencing rapid growth, driven by the country's large population, increasing healthcare expenditure, and government initiatives to improve healthcare access and quality. The Chinese government has been actively promoting the adoption of patient-centric care models and encouraging the development of innovative PSP solutions. The market is characterized by a mix of local and international players, with collaborations and partnerships being key strategies to navigate the complex healthcare landscape.

For instance, in December 2024, Tsinghua University’s Institute for AI Industry Research (AIR) launched an AI-powered Agent Hospital in China, set for a public pilot in 2025. This first-of-its-kind virtual hospital simulates real-world clinical workflows, enabling AI doctors to learn from virtual patients, review medical literature, and refine their skills through thousands of simulated cases. The AI doctors, spanning 21 specialties such as cardiology and emergency care, have demonstrated promising accuracy rates—88% for examinations, 95.6% for diagnoses, and 77.6% for treatments.

Germany Patient Support Programs (PSP) Market Trends

Germany continues to lead the patient support programs (PSP) market in Europe, owing to its advanced healthcare system, strong pharmaceutical industry presence, and supportive government policies. The country's focus on patient-centric care and the adoption of digital health solutions have been key drivers for the market growth. German pharmaceutical companies have been investing heavily in developing comprehensive PSPs to improve patient outcomes and enhance brand loyalty.

For instance, in January 2025, Germany’s Federal Ministry of Health, led by Prof. Karl Lauterbach, unveiled the “Action Plan for a Diverse, Inclusive, and Barrier-Free Healthcare System” to eliminate barriers in healthcare access for people with disabilities, marginalized groups, and caregivers. The plan aligns with Germany’s commitment to the UN Sustainable Development Goals and promotes equitable healthcare as a fundamental right, addressing challenges such as inaccessible facilities and complex medical communication.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments:

• In August 2024, Pfizer Inc., a global biopharmaceutical company, launched PfizerForAll, a digital platform aimed at simplifying access to healthcare in the U.S. The platform offers a seamless experience for patients managing common conditions like migraine, COVID-19, and flu, or seeking adult vaccines for preventable diseases.
• In July 2024, Sciensus continued its efforts to deliver innovative cancer treatments and patient support solutions across Europe. Through its Knowledge Hub, the company provides thought leadership on launching effective Patient Support Programs (PSPs) for rare disease patients, helping ensure access to care and improved outcomes. Sciensus empowers patients with at-home chemotherapy options and personalized care pathways, combining clinical excellence with digital solutions to simplify complex treatments and improve the quality of life.
• In June 2024, ZS, a leading global consulting and technology firm, released its 2024 Future of Health Report, outlining how patient support services are evolving into personalised, tech-driven solutions. The report highlights the growing influence of artificial intelligence (AI) and collaborative stakeholder models, and describes a shift towards e-commerce-like convenience, transparency, and tailored care. It also addresses the issue of healthcare professional (HCP) burnout by emphasising the need for streamlined workflows.
• In May 2024, IQVIA hosted a webinar as part of its Launch Excellence Web-Series, discussing how patient engagement and support programs are becoming critical for successful product launches. The session covered why patient engagement matters, how to address unmet patient needs, and how support programs drive therapy initiation and differentiation. With rising healthcare costs, increased competition, and adherence challenges, the webinar emphasised the importance of adopting patient-centric approaches in pharma.

Top Strategies Followed by Global Patient Support Programs (PSP) Market Players

• Established players in the global patient support programs (PSP) market are focusing on extensive research and development to innovate high-performance products. These companies invest heavily in R&D to stay ahead of the competition and offer cutting-edge solutions to their customers. For instance, leading PSP providers are developing advanced data analytics tools and AI-powered platforms to improve patient outcomes and streamline healthcare delivery processes.
  • For instance, In September 2023, IQVIA, a global healthcare data and technology company, released recommendations for enhancing Patient Support Programs (PSPs). The guidance emphasised an integrated PSP model featuring a single point of contact, fewer handoffs, and real-time insights to improve both patient and provider experiences. By focusing on individual patient needs and leveraging advanced technology, IQVIA aims to improve outcomes and streamline therapy journeys for patients.

• Mid-level players in the global patient support programs (PSP) market are concentrating on delivering cost-effective solutions to attract price-sensitive consumers. These companies focus on optimizing their production processes and leveraging economies of scale to offer quality products at competitive prices. Furthermore, collaborations with technology providers and other industry partners are key strategies for mid-level players to boost their technological capabilities, production capacity, and market presence.
  • For instance, in April 2025, The Health & Family Welfare Department, Government of Sikkim, India launched a comprehensive Emergency Helpline System and enhanced patient support services to improve healthcare accessibility and response across the state.

• Small-scale players in the global patient support programs (PSP) market are targeting niche markets by offering specialized products with unique features. These companies aim to differentiate themselves from larger competitors by addressing specific patient needs and providing innovative solutions. Additionally, small-scale players are adopting cutting-edge technologies, such as blockchain and machine learning, to enhance their offerings and remain competitive in the market.
  • For instance, in May 2023, Takeda Biopharmaceuticals India, a subsidiary of Japan-based global pharmaceutical company Takeda, launched the Sunrise Patient Services Program (PSP) for Hereditary Angioedema (HAE) patients in India. The Sunrise program covers four key areas—awareness, screening & diagnosis, treatment, and maintenance support—delivered through an independent patient services agency funded by Takeda.

Market Report Scope

Patient Support Programs (PSP) Market Dynamics

To learn more about this report, Request sample copy

Patient Support Programs (PSP) Market Driver - Increasing Prevalence of Chronic Diseases

The global healthcare landscape is witnessing a significant shift due to the alarming rise in the prevalence of chronic diseases. Conditions such as diabetes, cardiovascular disorders, respiratory illnesses, and cancer are becoming increasingly common, placing a substantial burden on patients, families, and healthcare systems worldwide. As a result, there is a growing demand for comprehensive patient support programs (PSPs) that can help individuals navigate the complex journey of managing chronic conditions. These programs offer a wide range of services, including disease education, medication adherence support, financial assistance, and emotional support, which are crucial for improving patient outcomes and quality of life.

Moreover, PSPs play a vital role in reducing healthcare costs by preventing complications, minimizing hospitalizations, and promoting self-management strategies. As the prevalence of chronic diseases continues to rise, the demand for patient support programs is expected to grow significantly, driving the expansion of the global patient support programs (PSP) market in the coming years. For instance, in March 2025, Eton Pharmaceuticals, a U.S.-based rare disease specialist, commercially launched Galzin (zinc acetate) capsules, the only USFDA-approved zinc therapy for Wilson disease, available exclusively through Optime Care. With the Eton Cares program, the company ensures patient support and $0 co-pay for eligible patients, addressing past challenges of access and affordability

Patient Support Programs (PSP) Market Opportunity: Growth in Telehealth and Digital Health Solutions

The increasing adoption of telehealth and digital health solutions presents a significant opportunity for the global patient support programs (PSP) market. The COVID-19 pandemic has accelerated the demand for remote healthcare services, and this trend is expected to continue in the post-pandemic era. Telehealth and digital health solutions enable healthcare providers to deliver PSPs remotely, reducing the need for in-person visits and improving patient access to care. These technologies can facilitate virtual consultations, remote monitoring, and patient education, allowing for more efficient and cost-effective delivery of PSPs.

Additionally, digital health platforms can provide patients with personalized support, such as medication reminders, symptom tracking, and access to educational resources. The integration of artificial intelligence and machine learning algorithms can further enhance the effectiveness of these platforms by providing insights into patient behavior and treatment outcomes. As a result, the growth in telehealth and digital health solutions is expected to drive innovation in the patient support programs (PSP) market, creating new opportunities for pharmaceutical companies, healthcare providers, and technology vendors to collaborate and develop patient-centric solutions.

Analyst Opinion (Expert Opinion)

• The Patient Support Programs (PSP) market is experiencing robust growth, driven by rising demand for personalized care solutions, the increasing burden of chronic diseases, and growing regulatory emphasis on patient-centric healthcare. Technological advancements, such as AI-driven patient engagement platforms, digital adherence tools, and data analytics, are enhancing the scalability and effectiveness of PSPs. Furthermore, regulatory support through value-based healthcare initiatives and reimbursement frameworks is encouraging the adoption of PSPs across therapeutic areas like oncology, rare diseases, and chronic care management. However, the market faces challenges such as data privacy concerns, patient enrolment barriers, and the need for seamless integration with existing healthcare systems. Opportunities lie in expanding PSP coverage in emerging markets, leveraging digital health tools for remote patient monitoring, and collaborating with payers to demonstrate measurable clinical outcomes.
• Key conferences like the World Orphan Drug Congress (Europe & U.S.), DIA Global Annual Meeting, and Eyeforpharma Patient Summit have facilitated crucial knowledge-sharing and networking among stakeholders in the PSP ecosystem. Real-world examples include Novartis’ “Support for Me” programme for heart failure patients, Sanofi’s MySupport initiative in oncology, and the NHS’ pilot digital adherence projects in the U.K. These initiatives highlight the strategic importance of PSPs in improving patient outcomes, fostering adherence, and aligning with global trends towards personalised and value-based care models.

Market Segmentation

•  Service Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Medication Adherence Support
  • Patient Education & Counseling
  • Disease-Specific Care Coordination
  • Remote Patient Monitoring
  • Financial Assistance & Reimbursement
  • Others
•  Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Rheumatology
  • Others (Diabetes, Infectious Diseases)
•  Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
•  Delivery Mode Insights (Revenue, USD Bn, 2020 - 2032)
  • In-person Services
  • Digital Solutions
  • Hybrid Models
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Assisted Living facilities
  • Healthcare Providers
  • Others (Research Centers, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Roche
  • Novartis
  • Pfizer
  • Merck & Co.
  • Johnson & Johnson
  • Sanofi
  • AstraZeneca
  • GSK (GlaxoSmithKline)
  • AbbVie
  • Amgen
  • Bayer
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical Company
  • Biogen

Sources

Primary Research Interviews:

• Healthcare professionals (oncologists, cardiologists, endocrinologists, etc.)
• Patient advocacy group leaders
• PSP coordinators and programme managers in hospitals and clinics
• Pharmacists and pharmaceutical care providers
• Healthcare IT system integrators

Databases:

• World Health Organization (WHO)
• World Bank
• UNICEF Data
• Global Burden of Disease Database
• Centers for Medicare & Medicaid Services (CMS)
• National Health Service (NHS) Digital and NHS England data
• National Health Service (NHS) Digital and NHS England data
• European Medicines Agency (EMA) Reports
• US Food and Drug Administration (FDA)

Magazines:

• PharmaTimes
• Pharmaceutical Executive
• The Pharma Letter
• Scrip Intelligence
• FiercePharma
• BioPharma Dive
• Pharmaceutical Technology

Journals:

• The Lancet
• BMJ (British Medical Journal)
• Journal of Medical Internet Research (JMIR)
• Patient Education and Counseling
• International Journal of Health Policy and Management
• Journal of Health Economics
• Frontiers in Public Health

Newspapers:

• The Guardian
• The New York Times
• Financial Times
• The Washington Post
• BBC News

Associations:

• International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
• European Patients’ Forum (EPF)
• National Health Council (NHC)
• Global Alliance for Patient Access (GAfPA)
• World Patients Alliance

Public Domain Sources:

• World Health Assembly (WHA) Reports
• UN Sustainable Development Goals (SDG) Reports
• Global Health Data Exchange (GHDx)
• WHO Global Action Plans (e.g., NCDs, Rare Diseases)
• Healthcare access reports from the Commonwealth Fund

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI existing repository of information for last 8 years